CoChat
Sign Up
Cited by 54Barrier Structure and Function StudiesLiver physiology and pathologyDrug Transport and Resistance Mechanisms

Blood‐Bile Barrier: Morphology, Regulation, and Pathophysiology

Open access
Pradhan-Sundd, Tirthadipa, Monga, Satdarshan Pal·2019·Gene Expression
DOI 10.3727/105221619x15469715711907PMC PMC6466181
Open this paper in CoChat — free account

Abstract

The term blood‐bile barrier (BBlB) refers to the physical structure within a hepatic lobule that compartmentalizes and hence segregates sinusoidal blood from canalicular bile. Thus, this barrier provides physiological protection in the liver, shielding the hepatocytes from bile toxicity and restricting the mixing of blood and bile. BBlB is primarily composed of tight junctions; however, adherens junction, desmosomes, gap junctions, and hepatocyte bile transporters also contribute to the barrier function of the BBlB. Recent findings also suggest that disruption of BBlB is associated with major hepatic diseases characterized by cholestasis and aberrations in BBlB thus may be a hallmark of many chronic liver diseases. Several molecular signaling pathways have now been shown to play a role in regulating the structure and function and eventually contribute to regulation of the BBlB function within the liver. In this review, we will discuss the structure and function of the BBlB, summarize the methods to assess the integrity and function of BBlB, discuss the role of BBlB in liver pathophysiology, and finally, discuss the mechanisms of BBlB regulation. Collectively, this review will demonstrate the significance of the BBlB in both liver homeostasis and hepatic dysfunction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3727/105221619x15469715711907

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 189

  1. [2]2. Wang L, Boyer JL. The maintenance and generation of membrane polarity in hepatocytes. Hepatology 2004; 39(4):892-9.
  2. [3]3. Kojima T, Yamamoto T, Murata M, Chiba H, Kokai Y, Sawada N. Regulation of the blood-biliary barrier: Inter­ action between gap and tight junctions in hepatocytes. Med Electron Microsc. 2003;36(3):157-64.
  3. [4]4. Schlegel N, Meir M, Heupel W-M, Holthöfer B, Leube RE, Waschke J. Desmoglein 2-mediated adhesion is required for intestinal epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G774-83.
  4. [5]5. Rao RK, Samak G. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 2013;1(4):e25718.
  5. [6]6. Kojima T, Murata M, Yamamoto T, Lan M, Imamura M, Son S, Takano K, Yamaguchi H, Ito T, Tanaka S, Chiba H, Hirata K, Sawada N. Tight junction protein and signal transduction pathway in hepatocytes. Histol Histopathol. 2009;24(3):1463-72.
  6. [7]7. LaRusso NF. Morphology, physiology, and biochemistry of biliary epithelia. Toxicol Pathol. 1996;24(1):84-9.
  7. [8]8. Roberts SK, Yano M, Ueno Y, et al. Cholangiocytes express the aquaporin CHIP and transport water via a channel-mediated mechanism. Proc Natl Acad Sci USA 1994;91(26):13009-13.
  8. [9]9. Garcia-Hernandez V, Quiros M, Nusrat A. Intestinal epithelial claudins: Expression and regulation in homeostasis and inflammation. Ann NY Acad Sci. 2017;1397(1):66-79.
  9. [11]11. Hartsock A, Nelson WJ. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008;1778(3):660-9.
  10. [12]12. Bauer H, Zweimueller-Mayer J, Steinbacher P, 12. Lametschwandtner A, Bauer HC. The dual role of zonula occludens (ZO) proteins. J Biomed Biotechnol. 2010; 2010:402593.
  11. [13]13. Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000;11(12):4131-42.
  12. [14]14. Huang S, Guo W, Zhou Z, Li J, Yang F, Wang J. Altered expression levels of occludin, claudin-1 and myosin light chain kinase in the common bile duct of pediatric patients with pancreaticobiliary maljunction. BMC Gastroenterol. 2016;16(1):7.
  13. [15]15. Traweger A, Fang D, Liu YC, et al. The tight junctionspecific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch. J Biol Chem. 2002;277(12): 10201-8.
  14. [17]17. properties of the gill epithelium. Mol Cell Endocrinol. 2017;439:457-66. 17. Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009; 10(8):235.
  15. [18]18. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999;96(2):511-6.
  16. [19]19. Angelow S, Ahlstrom R, Yu ASL. Biology of claudins. Am J Physiol Renal Physiol. 2008;295(4):F867-76.
  17. [20]20. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol Mech Dis. 2010;5:119-44.
  18. [21]21. Van Itallie CM, Anderson JM. Claudin interactions in and out of the tight junction. Tissue Barriers 2013;1(3): e25247.
  19. [22]22. Angelow S, Yu AS. Claudins and paracellular transport: An update. Curr Opin Nephrol Hypertens. 2007;16:459-64.
  20. [23]23. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: A tight junction disease. Gastroenterology 2004;127(5):1386-90.
  21. [24]24. Matsumoto K, Imasato M, Yamazaki Y, et al. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. Gastroenterology 2014;147(5):1134-45.
  22. [25]25. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Bio1. 1998;141(7):1539.
  23. [26]26. Sheth P, Delos Santos N, Seth A, LaRusso NF, Rao RK. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBPdependent mechanism. AJP Gastrointest Liver Physiol. 2007;293(1):G308-18.
  24. [28]28. Benedicto I, Molina-Jiménez F, Barreiro O, et al. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 2008;48(4):1044-53.
  25. [30]30. Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000;11(12):4131-42.
  26. [31]31. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: Leading or supporting players? Trends Cell Biol. 1999;9(7):268-73.
  27. [32]32. Al-Sadi R, Khatib K, Guo S, Ye D, Youssef M, Ma T. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2011;300(6):G1054-64.
  28. [33]33. Maly IP, Landmann L. Bile duct ligation in the rat causes upregulation of ZO-2 and decreased colocalization of claudins with ZO-1 and occludin. Histochem Cell Biol. 2008;129(3):289-99.
  29. [34]34. Pradhan-Sundd T, Zhou L, Vats R, et al. Dual catenin loss in murine liver causes tight junctional deregulation and - progressive intrahepatic cholestasis. Hepatology 2017; 67(6):2320-37.
  30. [35]35. Raleigh DR, Boe DM, Yu D, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol. 2011;193(3):565-82.
  31. [36]36. Woodfin A, Voisin M-B, Beyrau M, et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol. 2011;12(8):761-9.
  32. [37]37. Paris L, Tonutti L, Vannini C, Bazzoni G. Structural organization of the tight junctions. Biochim Biophys Acta 2007;1778(3):646-59.
  33. [38]38. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev. 2005;57(6):857-67.
  34. [39]39. Sugano Y, Takeuchi M, Hirata A, et al. Junctional adhesion molecule-A, JAM-A, is a novel cell-surface marker for long-term repopulating hematopoietic stem cells. Blood 2008;111(3):1167-72.
  35. [40]40. Braiterman LT, Heffernan S, Nyasae L, et al. JAM-A is both essential and inhibitory to development of hepatic polarity in WIF-B cells. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):G576-88.
  36. [41]41. Ebnet K. The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: A possible role for JAMs in endothelial cell polarity. J Cell Sci. 2003;116(19):3879-91.
  37. [42]42. Laukoetter MG, Nava P, Lee WY, et al. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med. 2007;204(13):3067-76.
  38. [43]43. Chavakis T, Preissner KT, Santoso S. Leukocyte transendothelial migration: JAMs add new pieces to the puzzle. Thromb Haemost. 2003;89(1):13-7.
  39. [44]44. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood J. 2016;127(7): 801-10.
  40. [45]45. Hintermann E, Bayer M, Ehser J, et al. Murine junctional adhesion molecules JAM-B and JAM-C mediate endothelial and stellate cell interactions during hepatic fibrosis. Cell Adhes Migr. 2016;10(4):419-33.
  41. [46]46. Coyne CB, Bergelson JM. CAR: A virus receptor within the tight junction. Adv Drug Deliv Rev. 2005;57(6): 869-82.
  42. [47]47. Raschperger E, Neve EPA, Wernerson A, Hultenby K, Pettersson RF, Majumdar A. The coxsackie and adenovirus receptor (CAR) is required for renal epithelial differentiation within the zebrafish pronephros. Dev Biol. 2008;313(1):455-64.
  43. [48]48. Raschperger E, Thyberg J, Pettersson S, Philipson L, Fuxe J, Pettersson RF. The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. Exp Cell Res. 2006;312(9):1566-80.
  44. [49]49. Cohen CJ, Shieh JTC, Pickles RJ, Okegawa T, Hsieh J-T, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001;98(26):15191-6.
  45. [50]50. Itoh M, Morita K, Tsukita S. Characterization of ZO-2 as a MAGUK family member associated with tight as well as adherens junctions with a binding affinity to occludin and a catenin. J Biol Chem. 1999;274(9):5981-6.
  46. [51]51. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: A high molecular weight polypeptide associated with the tight junction (Zonula - Occludens) in a variety of epithelia. J Cell Biol. 1986; 103(3):755-66.
  47. [52]52. Anerson JM, Stevenson BR, Jesaitis LA, Goodenough DA, Mooseker MS. Characterization of ZO-1, a protein component of the tight junction from mouse liver and Madin-Darby canine kidney cells. J Cell Biol. 1988; 106(4):1141-9.
  48. [53]53. Itoh M, Nagafuchi A, Yonemura S, Kitani-Yasuda T, Tsukita S, Tsukita S. The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction-associated protein in epithelial cells: cDNA cloning and immunoelectron microscopy. J Cell Biol. 1993;121(3):491-502.
  49. [54]54. Anderson JM, Glade JL, Stevenson BR, Boyer JL, Mooseker MS. Hepatic immunohistochemical localization of the tight junction protein ZO-1 in rat models of cholestasis. Am J Pathol. 1989;134(5):1055-62.
  50. [55]55. Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008;7:21.
  51. [56]56. Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326-8.
  52. [57]57. Carlton VEH, Harris BZ, Puffenberger EG, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet. 2003;34(1): 91-6.
  53. [58]58. Sambrotta M, Thompson RJ. Mutations in TJP2, encoding zona occludens 2, and liver disease. Tissue Barriers 2015;3(3):e1026537.
  54. [59]59. Umeda K, Ikenouchi J, Katahira-Tayama S, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006; 126(4):741-54.
  55. [60]60. Doctor RB, Nichols M. 3. The actin cytoskeleton in liver function. In: Bitter E, editor. Principles in medical biology, volume 15. The liver in biology and disease. Oxford, UK: Elsevier, 2004. p. 49-79.
  56. [61]61. Cui X, Zhang X, Yin Q, et al. F-actin cytoskeleton reorganization is associated with hepatic stellate cell activation. Mol Med Rep. 2014;9(5):1641-7.
  57. [62]62. Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ. Deconstructing the cadherin-catenin-actin complex. Cell 2005;123(5):889-901.
  58. [63]63. D'Souza-Schorey C. Disassembling adherens junctions: Breaking up is hard to do. Trends Cell Biol. 2005;15(1): 19-26.
  59. [64]64. Hinck L, Näthke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol. 1994;125(6):1327-40.
  60. [65]65. Herr KJ, Tsang YHN, Ong JWE, et al. Loss of a-catenin elicits a cholestatic response and impairs liver regeneration. Sci Rep. 2014;4:6835.
  61. [66]66. Behari J, Yeh T-H, Krauland L, et al. Liver-specific b -catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol. 2010; 176(2): 744-53.
  62. [67]67. Wickline ED, Du Y, Stolz DB, Kahn M, Monga SPS. g -Catenin at adherens junctions: Mechanism and biologic implications in hepatocellular cancer after b -catenin knockdown. Neoplasia 2013;15(4):421-34.
  63. [68]68. Reed MA, Zhou C, Muller CJ, Burgin TP, Tour JM. Conductance of a molecular junction. Science 1997;278: 252-4.
  64. [69]69. Zampighi G, Corless JM, Robertson JD. On gap junction structure. J Cell Biol. 1980;86(1):190-8. 3. Vinken M, Doktorova T, Decrock E, Leybaert L,
  65. [70]70. Vanhaecke T, Rogiers V. Gap junctional intercellular communication as a target for liver toxicity and carcinogenicity. Crit Rev Biochem Mol Biol. 2009;44(4):201-22.
  66. [71]71. Temme A, Stümpel F, Söhl G, et al. Dilated bile canaliculi and attenuated decrease of nerve-dependent bile secretion in connexin32-deficient mouse liver. Pflugers Arch. 2001;442(6):961-6.
  67. [72]72. Patel SJ, Milwid JM, King KR, et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 2012;30(2):179-83.
  68. [73]73. Green KJ, Getsios S, Troyanovsky S, Godsel LM. Intercellular junction assembly, dynamics, and homeostasis. Cold Spring Harb Perspect Biol. 2010;2(2):a000125.
  69. [74]74. Wickline ED, Awuah PK, Behari J, Ross M, Stolz DB, Monga SPS. Hepatocyte g -catenin compensates for conditionally deleted b -catenin at adherens junctions. J Hepatol. 2011;55(6):1256-62.
  70. [75]75. Arrese M, Ananthananarayanan M, Suchy FJ. Hepa­ tobiliary transport: Molecular mechanisms of development and cholestasis. Pediatr Res. 1998;44(2):141-7.
  71. [76]76. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol Med. 2003;9(12):558-64.
  72. [77]77. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009;50(12):2340-57.
  73. [78]78. Alrefai WA, Gill RK. Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm Res. 2007;10:1803-23. 12. Attili AF, Angelico M, Cantafora A, Alvaro D,
  74. [79]79. Capocaccia L. Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986;19(1):57-69.
  75. [80]80. Perez MJ, Britz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15(14):1677-89.
  76. [81]81. Raimondi F, Santoro P, Barone MV, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Liver Physiol. 2008;294(4):G906-13.
  77. [83]83. Luzzatto A. Hepatocyte differentiation during early fetal development in the rat. Cell Tissue Res. 1981;215(1): 133-42.
  78. [84]84. Wood RL. An electron microscope study of developing bile canaliculi in the rat. Anat Rec. 1965;151(4):507-29.
  79. [85]85. Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63:1023-37.
  80. [87]87. Son S, Kojima T, Decaens C, et al. Knockdown of tight junction protein claudin-2 prevents bile canalicular formation in WIF-B9 cells. Histochem Cell Biol. 2009; 131(3):411-24.
  81. [88]88. Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4): 1023-37.
  82. [89]89. Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3(3):1035-78.
  83. [90]90. Meier PJ, Stieger B. Molecular mechanisms in bile for­ mation. News Physiol Sci. 2000;15:89-93.
  84. [92]92. Decaens C, Durand M, Grosse B, Cassio D. Which in vitro models could be best used to study hepatocyte polarity? Biol Cell. 2008;100(7):387-98.
  85. [93]93. Okamoto H, Ishii M, Mano Y, et al. Confluent monolayers of bile duct epithelial cells with tight junctions. Hepatology 1995;22(1):153-9.
  86. [95]95. Goldblatt PJ, Gunning WT. Ultrastructure of the liver and biliary tract in health and disease. Ann Clin Lab Sci. 14(2):159-67.
  87. [96]96. Grisham JW, Nopanitaya W, Compagno J, Nägel AE. Scanning electron microscopy of normal rat liver: The surface structure of its cells and tissue components. Am J Anat. 1975;144:295-21.
  88. [97]97. Whittembury G, Rawlins FA. Evidence of a paracellular pathway for ion flow in the kidney proximal tubule: Electromicroscopic demonstration of lanthanum precipitate in the tight junction. Pflugers Arch. 1971;330(4):302-9.
  89. [98]98. Takakuwa Y, Kokai Y, Sasaki KI, et al. Bile canalicular barrier function and expression of tight-junctional molecules in rat hepatocytes during common bile duct ligation. Cell Tissue Res. 2002;307(2):181-9.
  90. [99]99. McCarter SD, Johnson DL, Kitt KN, Donohue C, Adams A, Wilson JM. Regulation of tight junction assembly and epithelial polarity by a resident protein of apical endosomes. Traffic 2010;11(6):856-66.
  91. [100]100. Higashi H, Brüstle O, Daley GQ, et al. Endothelial adherens junctions control tight junctions by VE-cadherinmediated upregulation of claudin-5. Cell 2009;8(4):1-2.
  92. [101]101. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ 2005;172(3):367-79.
  93. [102]102. Liu Y, Chen H-C, Yang S-M, et al. Visualization of hepatobiliary excretory function by intravital multiphoton microscopy. J Biomed Opt. 2011;12:014014.
  94. [103]103. Pradhan-Sundd T, Vats R, Russell JM, et al. Dysregulated bile transporters and impaired tight junctions during chronic liver injury in mice. Gastroenterology 2018; 155(4):1218-32.
  95. [104]104. Takaki Y, Hirai S, Manabe N, et al. Dynamic changes in protein components of the tight junction during liver regeneration. Cell Tissue Res. 2001;305(3):399-409.
  96. [105]105. Anderson JM. Leaky junctions and cholestasis: A tight correlation. Gastroenterology 1996;110(5):1662-5.
  97. [106]106. Sakisaka S, Kawaguchi T, Taniguchi E, et al. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001; 33(6):1460-8.
  98. [107]107. Landmann L. Cholestasis-induced alterations of the transand paracellular pathways in rat hepatocytes. Histochem Cell Biol. 1995;103(1):3-9.
  99. [108]108. Paganelli M, Stephenne X, Gilis A, et al. Neonatal ichthyosis and sclerosing cholangitis syndrome: Extremely variable liver disease severity from claudin-1 deficiency. J Pediatr Gastroenterol Nutr. 2011;53(3):350-4.
  100. [109]109. Sharanek A, Burban A, Burbank M, et al. Rho-kinase/ myosin light chain kinase pathway plays a key role in the - impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci Rep. 2016;6:24709.
  101. [110]110. Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury-What is the link? J Hepatol. 2017;67(3):619-31.
  102. [111]111. Chen X, Zhang C, Wang H, et al. Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice. Toxicol Appl Pharmacol. 2009;240(1):26-36.
  103. [112]112. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;14:62401-6.
  104. [113]113. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67.
  105. [114]114. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Prim. 2017;2;3:17006.
  106. [115]115. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009;83(4): 2011-4.
  107. [116]116. Findley MK, Koval M. Regulation and roles for claudinfamily tight junction proteins. IUBMB Life 2009;61(4): 431-7.
  108. [117]117. Benedicto I, Molina-Jimenez F, Bartosch B, et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol. 2009;83(16):8012-20.
  109. [118]118. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
  110. [120]120. Balogh J, Victor D, Asham EH, et al. Hepatocellular carcinoma: A review. J Hepatocell Carcinoma 2016;3:41-53. - Forner A, Llovet JM, Bruix J, Bruix J, Forner A, Llovet JM.
  111. [121]121. Hepatocellular carcinoma. Lancet 2012;391:1301-14.
  112. [122]122. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
  113. [123]123. Patonai A, Erdélyi-Belle B, Korompay A, et al. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Arch. 2011;458(6):679-88.
  114. [125]125. Zhong Y, Enomoto K, Tobioka H, Konishi Y, Satoh M, Mori M. Sequential decrease in tight junctions as revealed by 7H6 tight junction-associated protein during rat hepatocarcinogenesis. Jpn J Cancer Res. 1994;85(4):351-6.
  115. [126]126. Jakab C, Kiss A, Schaff Z, et al. Claudin-7 protein differentiates canine cholangiocarcinoma from hepatocellular carcinoma. Histol Histopathol. 2010;25(7):857-64.
  116. [127]127. Németh Z, Szász AM, Tátrai P, et al. Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers. J Histochem Cytochem. 2009;57(2):113-21.
  117. [128]128. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79.
  118. [129]129. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366(9493):1303-14.
  119. [130]130. Blechacz BRA, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12(1):131-50.
  120. [131]131. Takasawa K, Takasawa A, Osanai M, et al. Claudin-18 coupled with EGFR/ERK signaling contributes to the - malignant potentials of bile duct cancer. Cancer Lett. 2017;403:66-73.
  121. [133]133. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
  122. [134]134. Trasher T, Abelmalek M. Non-alcoholic fatty liver disease. N C Med J. 2016;77(3):216-9.
  123. [136]136. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62:S47-64.
  124. [138]138. Zhang M, Wang X-Q, Zhou Y-K, et al. Effects of oral Lactobacillus plantarum on hepatocyte tight junction structure and function in rats with obstructive jaundice. Mol Biol Rep. 2010;37(6):2989-99.
  125. [139]139. Sawada N. Tight junction-related human diseases. Pathol Int. 2013;63(1):1-12.
  126. [140]140. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-61.
  127. [141]141. Li MK, Crawford JM. The pathology of cholestasis. Semin Liver Dis. 2004;24(1):21-42.
  128. [142]142. Sakisaka S, Koga H, Sasatomi K, Mimura Y, Kawaguchi T, Tanikawa K. Biliary secretion of endotoxin and pathogenesis of primary biliary cirrhosis. Yale J Biol Med. 1997;70(4):403-8.
  129. [143]143. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1): 197-209.
  130. [144]144. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26-42.
  131. [145]145. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20(23):7312-24.
  132. [146]146. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: A pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4): 439-46.
  133. [147]147. Lee NP, Luk JM. Hepatic tight junctions: From viral entry to cancer metastasis. World J Gastroenterol. 2010; 16(3):289-95.
  134. [148]148. Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol. 2012;18(21):2609.
  135. [149]149. Sarathy J, Detloff SJ, Ao M, et al. The Yin and Yang of bile acid action on tight junctions in a model colonic epithelium. Physiol Rep. 2017;5(10):e13294.
  136. [150]150. Alexander JS, Dayton T, Davis C, et al. Activated T-lymphocytes express occludin, a component of tight junctions. Inflammation 1998;22(6):573-82.
  137. [151]151. Molitoris BA, Falk SA, Dahl RH. Ischemia-induced loss of epithelial polarity. Role of the tight junction. J Clin Invest. 1989;84(4):1334-9.
  138. [152]152. Benkoël L, Dodero F, Hardwigsen J, et al. Effect of ischemia-reperfusion on bile canalicular F-actin microfilaments in hepatocytes of human liver allograft: Image - analysis by confocal laser scanning microscopy. Dig Dis Sci. 2001;46(8):1663-7.
  139. [153]153. Brunner SM, Junger H, Ruemmele P, et al. Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. J Hepatol. 2013;58(6):1133-9.
  140. [154]154. Metz J, Aoki A, Merlo M, Forssmann WG. Morphological alterations and functional changes of interhepatocellular junctions induced by bile duct ligation. Cell Tissue Res. 1977;182(3):299-310.
  141. [155]155. Accatino L, Contreras A, Fernandez S, Quintana C. The effect of complete biliary obstruction on bile flow and bile acid excretion: Postcholestatic choleresis in the rat. J Lab Clin Med. 1979;93(5):706-17.
  142. [156]156. Rahner C, Stieger B, Landmann L. Structure-function correlation of tight junctional impairment after intrahe­ patic and extrahepatic cholestasis in rat liver. Gastro­ enterology 1996;110(5):1564-78.
  143. [157]157. Guntaka SR, Samak G, Seth A, Larusso NF, Rao R. Epidermal growth factor protects the apical junctional complexes from hydrogen peroxide in bile duct epithelium. Lab Invest. 2011;91(9):1396-1409.
  144. [158]158. Sheth P, Samak G, Shull JA, Seth A, Rao R. Protein phosphatase 2A plays a role in hydrogen peroxide-induced disruption of tight junctions in Caco-2 cell monolayers. Biochem J. 2009;421(1):59-70.
  145. [159]159. Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3(3):1035-78.
  146. [160]160. Ballatori N, Truong AT. Altered hepatic junctional permeability, bile acid excretion and glutathione efflux during oxidant challenge. J Pharmacol Exp Ther. 1989; 251(3):1069-75.
  147. [161]161. Ballatori N, Truong AT. Glutathione as a primary osmotic driving force in hepatic bile formation. Am J Physiol. 1992;263:G617-24.
  148. [162]162. Juric M, Xiao F, Amasheh S, et al. Increased epithelial permeability is the primary cause for bicarbonate loss in inflamed murine colon. Inflamm Bowel Dis. 2013; 19(5):904-11. - Prieto J, Garcia N, Marti-Climent JM, Penuelas I,
  149. [163]163. Richter JA, Medina JF. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999;117(1):167-72.
  150. [164]164. Wang R, Sheps JA, Ling V. ABC Transporters, bile acids, and inflammatory stress in liver cancer. Curr Pharm Biotechnol. 2011;12(4):636-46.
  151. [165]165. Krishnamurthy N, Kurzrock R. Targeting the Wnt/betacatenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 2017;62:50-60.
  152. [166]166. Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol. 2012;18(36):4985-93.
  153. [167]167. Woodhead JL, Yan K, Siler SQ, et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol. 2014; 5:240.
  154. [168]168. Hofmann AF. Bile acids: The good, the bad, and the ugly. News Physiol Sci. 1999;14:24-9.
  155. [169]169. Chen X, Oshima T, Tomita T, et al. Acidic bile salts modulate the squamous epithelial barrier function by modulating tight junction proteins. Am J Physiol Gastrointest Liver Physiol. 2011;301(2):G203-9.
  156. [170]170. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxy­ cholic acid aggravates bile infarcts in bile duct-ligated - and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123(4):1238-51.
  157. [171]171. Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: Final data for 2013. Natl Vital Stat Rep. 2016;64(2):1-119.
  158. [172]172. Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology 2004;39(2): 476-83.
  159. [173]173. Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2012;28(3): 203-8. - Nicolas CT, Wang Y, Nyberg SL. Cell therapy in
  160. [174]174. chronic liver disease. Curr Opin Gastroenterol. 2016; 32(3):189-94.
  161. [175]175. Arora G, Keeffe EB. Management of chronic liver failure until liver transplantation. Med Clin North Am. 2008;92(4):839-60.
  162. [176]176. Fox RK. When to consider liver transplant during the management of chronic liver disease. Med Clin North Am. 2014;98(1):153-68.
  163. [177]177. Solà E, Ginès P. Chronic kidney disease: A major concern in liver transplantation in the XXI century. J Hepatol. 2014;61(2):196-7.
  164. [178]178. Gamal W, Treskes P, Samuel K, et al. Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. Sci Rep. 2017;7:37541.
  165. [180]180. Briskey D, Heritage M, Jaskowski L-A, et al. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2016;9(4):463-72.
  166. [181]181. Zhao H, Zhao C, Dong Y, et al. Inhibition of miR122a by Lactobacillus rhamnosus GG culture supernatant increases intestinal occludin expression and protects mice from alcoholic liver disease. Toxicol Lett. 2015;234(3): 194-200.
  167. [182]182. Xue L, He J, Gao N, et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:1-13.
  168. [183]183. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517-26.
  169. [184]184. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005; 25(10):2020-30.
  170. [185]185. Eloranta JJ, Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis. Physiology (Bethesda) 2008;23(5):286-95.
  171. [186]186. Wang YD, Chen WD, Moore DD, Huang W. FXR: A metabolic regulator and cell protector. Cell Res. 2008;18(11):1087-95.
  172. [187]187. Neuschwander-Tetri BA. Targeting the FXR nuclear receptor to treat liver disease. Gastroenterology 2015; 148(4):704-6.
  173. [189]189. Ceulemans LJ, Verbeke L, Decuypere J-P, et al. Farnesoid X receptor activation attenuates intestinal ischemia reperfusion injury in rats. PLoS One 2017;12(1):e0169331.
  174. [191]191. Tsukita S, Furuse M, Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol. 1999;11(5):628-33.
  175. [192]192. Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol. 2003;4(3):225-36.
  176. [193]193. Behari J, Yeh T-H, Krauland L, et al. Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol. 2010; 176(2):744-53.
  177. [194]194. Kim SK. Tight junctions, membrane-associated guanylate kinases and cell signaling. Curr Opin Cell Biol. 1995;7(5):641-9.
  178. [195]195. Kale G, Naren AP, Sheth P, Rao RK. Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3. Biochem Biophys Res Commun. 2003;302(2):324-9.
  179. [196]196. Rao R. Occludin phosphorylation in regulation of epithelial tight junctions. Ann NY Acad Sci. 2009;1165:62-8.
  180. [197]197. Raleigh DR, Boe DM, Yu D, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol. 2011;193(3):565-82.
  181. [199]199. Suzuki T, Elias BC, Seth A, et al. PKC regulates occludin phosphorylation and epithelial tight junction integrity. Proc Natl Acad Sci USA 2009;106(1):61-6.
  182. [200]200. Basuroy S, Sheth P, Kuppuswamy D, Balasubramanian S, Ray RM, Rao RK. Expression of kinase-inactive c-Src 12. delays oxidative stress-induced disassembly and accelerates calcium-mediated reassembly of tight junctions in the Caco-2 cell monolayer. J Biol Chem. 2003;278(14): 11916-24.
  183. [201]201. Walsh SV, Hopkins AM, Chen J, Narumiya S, Parkos CA, Nusrat A. Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia. Gastroenterology 2001;121(3):566-79.
  184. [202]202. Seth A, Sheth P, Elias BC, Rao R. Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer. J Biol Chem. 2007;282(15):11487-98.
  185. [203]203. Jia H, Liu Y , Yan W, Jia J. PP4 and PP2A regulate Hedgehog signaling by controlling Smo and Ci phosphorylation. Development 2009;136:307-16.
  186. [204]204. Wang N, Leung HT, Mazalouskas MD, Watkins GR, Gomez RJ, Wadzinski BE. Essential roles of the tap42regulated protein phosphatase 2a (PP2A) family in wing imaginal disc development of drosophila melanogaster. PLoS One 2012;7(6): e38569.
  187. [205]205. Pradhan-Sundd T, Zhou L, Vats R, et al. Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis. Hepatology 2018; 67(6):2320-37.
  188. [206]206. Shen L. Role of epithelial cells in initiation and propagation of intestinal inflammation. Eliminating the static: Tight junction dynamics exposed. AJP Gastrointest Liver Physiol. 2006;290(4):G577-82.
  189. [207]207. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGF b receptors controls epithelial cell plasticity. Science 2005;307(5715):1603-9.

Cited by

Sorted by citations

Authors
Pradhan-Sundd, T., & Monga, S. P.
Affiliations
  • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • University of Pittsburgh (US)
ORCID
Monga, Satdarshan Pal
Venue
Gene Expression
Publisher
Xia & He Publishing
Published
2019-04-18
Volume
19
Issue
2
Pages
69-87
ISSN
1052-2166 (ISSN-L)
DOI
10.3727/105221619x15469715711907
PMC
PMC6466181
OpenAlex
W2911184404
Cited by
54
References
6
Citations by year
2026: 3 · 2025: 8 · 2024: 12 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 3 · 2019: 5 · 2017: 1
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Gene Expression (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01CA204586)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100287, R01DK062277)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
tight junctions, cholestasis, chronic liver disease, signaling pathways, liver homeostasis
MeSH terms
Animals, Bile Canaliculi, Blood Vessels, Humans, Intercellular Junctions, Liver, Liver Diseases, Hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review